The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
نویسندگان
چکیده
منابع مشابه
The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
Background Genetically engineered T cells have broadened the opportunity for use of T cell immunotherapy in cancer patients. The possibility of improving T cell efficacy via introduction of additional genes potentially gives them an advantage over TIL. Studies in adoptive T cell transfer suggest that persistence is fundamental to the efficacy of this therapy. This Phase I clinical trial uses TC...
متن کاملCancer regression in patients after transfer of genetically engineered lymphocytes.
Through the adoptive transfer of lymphocytes after host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting. Here we report the ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a ...
متن کاملepistemic modality in english and persian academic writing: a cross-linguistic study of genre on the notion of transfer
چکیده حیطه ی نوشتار دانشگاهی اخیرا شاهد تغییرات عمده ای از غیرشخصی بودن (عینی بودن) به شخصی بودن بوده است. شخصی بودن متون دانشگاهی اهمیت استفاده از وجهیت معرفتی را برجسته می سازد چرا که? وجهیت معرفتی? بر اساس یکی از تعاریف ارائه شده از این مقوله? ارتباط تنگاتنگی با شخصی بودن داشته و به عنوان بیان نظر شخصی گوینده در مورد جز گزاره ای گفته در نظر گرفته میشود. بنابراین? با در نظر داشتن نقاط مشترک...
15 صفحه اولA phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients
Trastuzumab has been widely used among the breast cancer patients with human epidermal growth factor receptor 2 (HER2) overexpression. The genetically engineered trastuzumab traded as Cipterbin® was developed in China since 2003. We have disclosed the phase I clinical trial data of safety, pharmacokinetic profile (PK) in patients with metastasis breast cancer. Subjects identified as HER2 strong...
متن کاملSafety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
PURPOSE The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal for ImmunoTherapy of Cancer
سال: 2015
ISSN: 2051-1426
DOI: 10.1186/2051-1426-3-s2-p168